The European Patent Office (EPO) has granted a patent to Seegene's Dual Priming Oligonucleotide (DPO) technology.
Seegene multiplex molecular diagnostics (M-MoDx) assays’ which are based on DPO technology can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility.
The tests are used to detect infectious diseases like respiratory diseases, sexually transmitted infections, tuberculosis and also used in oncology diagnostics, pharmacogenetics tests and prognostic genetic tests.
Seegene CEO Jong-Yoon Chun said DPO enables tests to dentify and differentiate infectious agents, as well as their resistance profile, at the same time, in a single test and in a single tube.